Caladrius Biosciences, Inc. (CLBS) News Headlines

▮ More

Date

Headline

6/4/2019 8:38:17 AM Caladrius Biosciences Completes Enrollment In Phase 2 ESCaPE-CMD Trial For Coronary Microvascular Dysfunction

5/14/2019 6:43:19 AM WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target

11/12/2018 9:05:09 PM OPK To Report Data In Q1, EIDX Cheers Investors, Busy Year Ahead For VRCA

11/8/2018 8:32:16 AM Caladrius Biosciences Appoints Cynthia Schwalm To Board

6/20/2018 9:25:52 PM NEPT Hits A High, CLBS Up 118% In 2 Days, APEN Abuzz, Busy Days Ahead For TSRO

6/20/2018 9:40:21 AM Caladrius Biosciences Inc. (CLBS) Has Jumped To A New High On FDA News

6/19/2018 8:39:40 PM CLBS Firing On All Cylinders, SLDB Gets Ignited, SRPT Walks The Talk, SRRK Rocks

6/19/2018 8:04:25 AM Caladrius Gets FDA Regenerative Medicine Advanced Therapy Designation For CD34+ Cell Therapy For Refractory Angina

5/10/2018 4:17:15 PM EARNINGS SUMMARY: Details of Caladrius Biosciences, Inc. Q1 Earnings Report

5/10/2018 4:09:52 PM Caladrius Biosciences Q1 Net Loss From Cont Ops $5.0 Mln Or $0.52 Per Share

4/10/2018 8:04:22 AM Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation In Japan For CLBS12 For Critical Limb Ischemia

3/22/2018 4:08:54 PM EARNINGS SUMMARY: Details of Caladrius Biosciences, Inc. Q4 Earnings Report

3/22/2018 4:08:37 PM Caladrius Biosciences Q4 Loss/share $0.29 Vs. Loss $0.73 Year Ago

3/13/2018 8:04:54 AM Caladrius Biosciences Doses First Patient With CLBS12 In Phase 2 Critical Limb Ischemia Trial In Japan

3/6/2018 8:17:52 AM Caladrius Acquires Rights To Data Set, Filings For CD34+ Cell Therapy Program

3/6/2018 8:05:34 AM Caladrius Acquires License To Late Stage CD34+ Cell Therapy Program For Treatment Of Refractory Angina

Older Articles